Background: The therapeutic goal of clinical remission in patients with moderate to severe ulcerative colitis (UC) is achieved after biological therapy only in 16–39%. Individualization of therapeutic intervention would benefit from prediction of early response. Study Objective: The primary objective of our study was to assess golimumab (GLM) trough serum level of ≥2.5 μg/mL in combination with a reduction of faecal calprotectin (FC) of ≥50% at week 6 compared to baseline to predict clinical response at week 26 after regular GLM intake. Methods: Patients with moderate to severe active UC and planned GLM treatment were recruited for a prospective, multicentre, observational study in Germany. Prediction of clinical response was assessed by FC and GLM trough level. Missing data were imputed as therapy failure according to the last observation carried forward method. Results: Fifty nine patients have been enrolled. 54% of patients were anti-TNF naïve. Clinical response at week 6 was a significant predictor for achieving clinical response at week 26 (odds ratio [OR] 10.97, confidence interval [CI], 2.96–40.68; p < 0.001). Moreover, patients with a GLM trough level of ≥2.5 μg/mL and a ≥50% reduction of FC at week 6 had an OR of 5.33 (95% CI, 0.59–47.84) to achieve clinical response at week 26. Conclusion: Clinical response at week 6 is the best predictive marker for achieving clinical response at week 26. Consideration of significant reduction of FC and trough GLM serum levels could improve prediction of response.

1.
Harbord
M
,
Eliakim
R
,
Bettenworth
D
,
Karmiris
K
,
Katsanos
K
,
Kopylov
U
,
.
Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 2: current management
.
J Crohns Colitis
.
2017
;
11
(
7
):
769
84
.
2.
Sandborn
WJ
,
Su
C
,
Sands
BE
,
D’Haens
GR
,
Vermeire
S
,
Schreiber
S
,
.
Tofacitinib as induction and maintenance therapy for ulcerative colitis
.
N Engl J Med
.
2017
;
376
(
18
):
1723
36
.
3.
Reinisch
W
,
Sandborn
WJ
,
Hommes
DW
,
D’Haens
G
,
Hanauer
S
,
Schreiber
S
,
.
Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial
.
Gut
.
2011
;
60
(
6
):
780
7
.
4.
Sandborn
WJ
,
van Assche
G
,
Reinisch
W
,
Colombel
JF
,
D’Haens
G
,
Wolf
DC
,
.
Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis
.
Gastroenterology
.
2012
;
142
(
2
):
257
3
.
5.
Rutgeerts
P
,
Sandborn
WJ
,
Feagan
BG
,
Reinisch
W
,
Olson
A
,
Johanns
J
,
.
Infliximab for induction and maintenance therapy for ulcerative colitis
.
N Engl J Med
.
2005
;
353
(
23
):
2462
76
.
6.
Sandborn
WJ
,
Feagan
BG
,
Marano
C
,
Zhang
H
,
Strauss
R
,
.
Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis
.
Gastroenterology
.
2014
;
146
(
1
):
85
95
; quiz e14-5 https://doi.org/10.1053/j.gastro.2013.05.048.
7.
Feagan
BG
,
Rutgeerts
P
,
Sands
BE
,
Hanauer
S
,
Colombel
JF
,
Sandborn
WJ
,
.
Vedolizumab as induction and maintenance therapy for ulcerative colitis
.
N Engl J Med
.
2013
;
369
(
8
):
699
710
.
8.
Sands
BE
,
Peyrin-Biroulet
L
,
Loftus
EV
Jr
,
Danese
S
,
Colombel
JF
,
Toruner
M
,
.
Vedolizumab versus adalimumab for moderate-to-severe ulcerative colitis
.
N Engl J Med
.
2019
;
381
(
13
):
1215
26
.
9.
Atreya
R
,
Neumann
H
,
Neufert
C
,
Waldner
MJ
,
Billmeier
U
,
Zopf
Y
,
.
In vivo imaging using fluorescent antibodies to tumor necrosis factor predicts therapeutic response in Crohn’s disease
.
Nat Med
.
2014
;
20
(
3
):
313
8
.
10.
Coleta
MPM
,
Mazza
S
,
Facciotti
F
,
Geginat
J
,
Fantini
M
,
Vecchi
M
,
.
Immunologic predictors of response to Vedolizumab treatment in patients with inflammatory bowel disease: results of a phase IV prospective interventional trial
.
San Diego
:
DDW
;
2019
. p.
836
.
11.
Aden
KRA
,
Waschina
S
,
Walker
A
,
Nunez
A
,
Zimmermann
J
,
Franke
A
,
.
Gut Microbial metabolic functions are associated with Anti-TNF efficacy in IBD patients
.
Vienna
:
UEGW
;
2019
.
12.
Cornillie
F
,
Hanauer
SB
,
Diamond
RH
,
Wang
J
,
Tang
KL
,
Xu
Z
,
.
Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial
.
Gut
.
2014
;
63
(
11
):
1721
7
.
13.
Papamichael
K
,
Rivals-Lerebours
O
,
Billiet
T
,
Vande Casteele
N
,
Gils
A
,
Ferrante
M
,
.
Long-term outcome of patients with ulcerative colitis and primary non-response to infliximab
.
J Crohns Colitis
.
2016
;
10
(
9
):
1015
23
.
14.
Gonczi
L
,
Vegh
Z
,
Golovics
PA
,
Rutka
M
,
Gecse
KB
,
Bor
R
,
.
Prediction of short: and medium-term efficacy of biosimilar infliximab therapy. Do trough levels and antidrug antibody levels or clinical and biochemical markers play the more important role
.
J Crohns Colitis
.
2017
;
11
(
6
):
697
705
.
15.
Vande Casteele
N
,
Khanna
R
,
Levesque
BG
,
Stitt
L
,
Zou
GY
,
Singh
S
,
.
The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn’s disease
.
Gut
.
2015
;
64
(
10
):
1539
45
. https://doi.org/10.1136/gutjnl-2014-307883.
16.
Karmiris
K
,
Paintaud
G
,
Noman
M
,
Magdelaine–Beuzelin
C
,
Ferrante
M
,
Degenne
D
,
.
Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn’s disease
.
Gastroenterology
.
2009
;
137
(
5
):
1628
40
.
17.
Adedokun
OJ
,
Sandborn
WJ
,
Feagan
BG
,
Rutgeerts
P
,
Xu
Z
,
Marano
CW
,
.
Association between serum concentration of infliximab and efficacy in adult patients with ulcerative colitis
.
Gastroenterology
.
2014
;
147
(
6
):
1296
307.e5
.
18.
Schulze
H
,
Esters
P
,
Hartmann
F
,
Stein
J
,
Christ
C
,
Zorn
M
,
.
A prospective cohort study to assess the relevance of vedolizumab drug level monitoring in IBD patients
.
Scand J Gastroenterol
.
2018
;
53
:
670
6
.
19.
Yacoub
W
,
Williet
N
,
Pouillon
L
,
Di-Bernado
T
,
De Carvalho Bittencourt
M
,
Nancey
S
,
.
Early vedolizumab trough levels predict mucosal healing in inflammatory bowel disease: a multicentre prospective observational study
.
Aliment Pharmacol Ther
.
2018
;
47
(
7
):
906
12
.
20.
Restellini
S
,
Khanna
R
,
Afif
W
.
Therapeutic drug monitoring with ustekinumab and vedolizumab in inflammatory bowel disease
.
Inflamm Bowel Dis
.
2018
;
24
(
10
):
2165
72
.
21.
Drobne
DZJ
,
Kurent
T
,
Hanzel
J
,
Sever
N
,
Javornik
K
.
Peak Ustekinumab concentration after intravenous loding dose predicts faecal calprotectin normalization in Crohn’s Disease: potential role for therapeutic drug monitoring
.
UEGW Barcelona
.
2019
.
22.
Adedokun
OJ
,
Xu
Z
,
Liao
S
,
Strauss
R
,
Reinisch
W
,
Feagan
BG
,
.
Population pharmacokinetics and exposure-response modeling of golimumab in adults with moderately to severely active ulcerative colitis
.
Clin Ther
.
2020
;
42
(
1
):
157
74.e4
.
23.
Mooiweer
E
,
Fidder
HH
,
Siersema
PD
,
Laheij
RJF
,
Oldenburg
B
.
Fecal hemoglobin and calprotectin are equally effective in identifying patients with inflammatory bowel disease with active endoscopic inflammation
.
Inflamm Bowel Dis
.
2014
;
20
(
2
):
307
14
.
24.
Wright
EK
,
Kamm
MA
,
De Cruz
P
,
Hamilton
AL
,
Ritchie
KJ
,
Krejany
EO
,
.
Measurement of fecal calprotectin improves monitoring and detection of recurrence of Crohn's disease after surgery
.
Gastroenterology
.
2015
;
148
(
5
):
938
47.e1
.
25.
De Vos
M
,
Dewit
O
,
D'Haens
G
,
Baert
F
,
Fontaine
F
,
Vermeire
S
,
.
Fast and sharp decrease in calprotectin predicts remission by infliximab in anti-TNF naive patients with ulcerative colitis
.
J Crohn’s Colitis
.
2012
;
6
(
5
):
557
62
.
26.
Drabik
A
,
Sturm
A
,
Blomacher
M
,
Helwig
U
.
Early monitoring of response (MORE) to golimumab therapy based on fecal calprotectin and trough serum levels in patients with ulcerative colitis: a multicenter prospective study
.
JMIR Res Protoc
.
2016
;
5
(
2
):
e124
.
27.
Cook
RJ
,
Zeng
L
,
Yi
GY
.
Marginal analysis of incomplete longitudinal binary data: a cautionary note on LOCF imputation
.
Biometrics
.
2004
;
60
(
3
):
820
8
.
28.
Travis
S
,
Feagan
BG
,
Peyrin-Biroulet
L
,
Panaccione
R
,
Danese
S
,
Lazar
A
,
.
Effect of adalimumab on clinical outcomes and health-related quality of life among patients with ulcerative colitis in a clinical practice setting: results from InspirADA
.
J Crohns Colitis
.
2017
;
11
:
1317
25
.
29.
Fumery
M
,
Singh
S
,
Dulai
PS
,
Gower-Rousseau
C
,
Peyrin-Biroulet
L
,
Sandborn
WJ
.
Natural history of adult ulcerative colitis in population-based cohorts: a systematic review
.
Clin Gastroenterol Hepatol
.
2018
;
16
(
3
):
343
56.e3
.
30.
Cosnes
J
,
Gower-Rousseau
C
,
Seksik
P
,
Cortot
A
.
Epidemiology and natural history of inflammatory bowel diseases
.
Gastroenterology
.
2011
;
140
(
6
):
1785
94.e4
.
31.
Pariente
B
,
de Chambrun
GP
,
Krzysiek
R
,
Desroches
M
,
Louis
G
,
De Cassan
C
,
.
Trough levels and antibodies to infliximab may not predict response to intensification of infliximab therapy in patients with inflammatory bowel disease
.
Inflamm Bowel Dis
.
2012
;
18
(
7
):
1199
206
.
32.
Gordon
IO
,
Agrawal
N
,
Willis
E
,
Goldblum
JR
,
Lopez
R
,
Allende
D
,
.
Fibrosis in ulcerative colitis is directly linked to severity and chronicity of mucosal inflammation
.
Aliment Pharmacol Ther
.
2018
;
47
(
7
):
922
39
.
33.
D'Haens
G
,
Vermeire
S
,
Lambrecht
G
,
Baert
F
,
Bossuyt
P
,
Pariente
B
,
.
Increasing infliximab dose based on symptoms, biomarkers, and serum drug concentrations does not increase clinical, endoscopic, and corticosteroid-free remission in patients with active luminal crohn's disease
.
Gastroenterology
.
2018
;
154
(
5
):
1343
51.e1
.
34.
Vande Casteele
N
,
Ferrante
M
,
Van Assche
G
,
Ballet
V
,
Compernolle
G
,
Van Steen
K
,
.
Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease
.
Gastroenterology
.
2015
;
148
(
7
):
1320
9.e3
.
35.
Papamichael
K
,
Cheifetz
AS
,
Melmed
GY
,
Irving
PM
,
Vande Casteele
N
,
Kozuch
PL
,
.
Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients With Inflammatory Bowel Diseases
.
Clin Gastroenterol Hepatol
.
2019
;
17
(
9
):
1655
68.e3
.
36.
Vande Casteele
N
,
Khanna
R
.
Therapeutic drug monitoring of golimumab in the treatment of ulcerative colitis
.
Pharm Res
.
2017
;
34
(
8
):
1556
63
.
37.
Adedokun
OJ
,
Xu
Z
,
Marano
CW
,
Strauss
R
,
Zhang
H
,
Johanns
J
,
.
Pharmacokinetics and exposure-response relationship of golimumab in patients with moderately-to-severely active ulcerative colitis: results from phase 2/3 PURSUIT induction and maintenance studies
.
J Crohns Colitis
.
2017
;
11
(
1
):
35
46
.
38.
Sandborn
WJ
,
Feagan
BG
,
Marano
C
,
Zhang
H
,
Strauss
R
,
Johanns
J
,
.
Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis
.
Gastroenterology
.
2014
;
146
(
1
):
96
109 e1
.
39.
Rutgeerts
P
,
Feagan
BG
,
Marano
CW
,
Padgett
L
,
Strauss
R
,
Johanns
J
,
.
Randomised clinical trial: a placebo-controlled study of intravenous golimumab induction therapy for ulcerative colitis
.
Aliment Pharmacol Ther
.
2015
;
42
(
5
):
504
14
.
40.
Detrez
I
,
Dreesen
E
,
Van Stappen
T
,
de Vries
A
,
Brouwers
E
,
Van Assche
G
,
.
Variability in golimumab exposure: a “real-life” observational study in active ulcerative colitis
.
J Crohns Colitis
.
2016
;
10
(
5
):
575
81
.
41.
Magro
F
,
Lopes
S
,
Silva
M
,
Coelho
R
,
Portela
F
,
Branquinho
D
,
.
Low golimumab trough levels at week 6 are associated with poor clinical, endoscopic and histological outcomes in ulcerative colitis patients: pharmacokinetic and pharmacodynamic sub-analysis of the evolution study
.
J Crohn's Colitis
.
2019
;
13
(
11
):
1387
93
.
42.
Philip
G
,
Cornillie
F
,
Adedokun
JO
,
Melsheimer
R
,
Rutgeerts
P
,
Colombel
JF
,
.
Early dose optimisation of golimumab in nonresponders to induction treatment for ulcerative colitis is effective and supported by pharmacokinetic data
.
J Crohns Colitis
.
2019
;
13
(
10
):
1257
64
.
43.
World Medical Association
.
WMA Declaration of Helsinki. Ethical Principles for medical research involving human subjects
.
JAMA
.
2013
;
310
(
20
):
2191
4
.
You do not currently have access to this content.